A detailed history of Miracle Mile Advisors, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Miracle Mile Advisors, LLC holds 4,589 shares of HALO stock, worth $321,367. This represents 0.01% of its overall portfolio holdings.

Number of Shares
4,589
Previous 4,600 0.24%
Holding current value
$321,367
Previous $239,000 40.59%
% of portfolio
0.01%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Oct 20, 2025

SELL
$52.92 - $78.28 $582 - $861
-11 Reduced 0.24%
4,589 $336,000
Q2 2025

Jul 22, 2025

BUY
$47.91 - $70.14 $7,234 - $10,591
151 Added 3.39%
4,600 $239,000
Q1 2025

Apr 14, 2025

BUY
$47.74 - $65.16 $1,432 - $1,954
30 Added 0.68%
4,449 $283,000
Q4 2024

Jan 13, 2025

BUY
$42.57 - $61.09 $3,150 - $4,520
74 Added 1.7%
4,419 $211,000
Q2 2024

Jul 18, 2024

BUY
$37.81 - $52.4 $164,284 - $227,678
4,345 New
4,345 $227,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $9.75B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Miracle Mile Advisors, LLC Portfolio

Follow Miracle Mile Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Miracle Mile Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Miracle Mile Advisors, LLC with notifications on news.